As it was based on a single, large, high-quality trial, it captured all of the associations between patient characteristics and tumour test results, such as the relationship between age and MLH1 hypermethylation, and the possibility of differential test performance for pathogenic variants in different MMR genes. The gene discussed is MLH1; the disease is neoplasm.